"Tägliche Einnahme eines Multivitamins verringert das Krebsrisiko signifikant
Forscher empfehlen Männern die Einnahme von Multivitamin-Supplementen zur Krebsvorbeugung
Eine große amerikanische Studie (Physicians` Health Study II), die im Rahmen des laufenden amerikanischen Krebskongresses vorgestellt wurde und in einer hoch renommierten Zeitschrift veröffentlicht ist, hat gezeigt, dass die tägliche Einnahme eines Multivitaminpräparates zu einer signifikanten Verringerung des Krebsrisikos bei Männern führt...."
Hohenheimer Ernährungsinformation (HEI)
Institut für Biologische Chemie und Ernährungswissenschaft
Prof. Dr. med. Hans K. Biesalski - Direktor
Universität Hohenheimhttp://www.presseportal.de/pm/77838/2346334/taegliche-einnahme-eines-multivitamins-verringert-das-krebsrisiko-signifikant-forscher-empfehlen
"Multivitamins in the Prevention of Cancer in MenThe Physicians' Health Study II Randomized Controlled Trial
Original Contribution | ONLINE FIRST
Multivitamins in the Prevention of Cancer in MenThe Physicians' Health Study II Randomized Controlled Trial FREE ONLINE FIRST
J. Michael Gaziano, MD, MPH; Howard D. Sesso, ScD, MPH; William G. Christen, ScD; Vadim Bubes, PhD; Joanne P. Smith, BA; Jean MacFadyen, BA; Miriam Schvartz, MD; JoAnn E. Manson, MD, DrPH; Robert J. Glynn, ScD; Julie E. Buring, ScD
[+] Author Affiliations
JAMA. 2012;():1-10. doi:10.1001/jama.2012.14641.
Published online October 17, 2012
ABSTRACT
Context Multivitamin preparations are the most common dietary supplement, taken by at least one-third of all US adults. Observational studies have not provided evidence regarding associations of multivitamin use with total and site-specific cancer incidence or mortality.
Objective To determine whether long-term multivitamin supplementation decreases the risk of total and site-specific cancer events among men.
Design, Setting, and Participants A large-scale, randomized, double-blind, placebo-controlled trial (Physicians' Health Study II) of 14 641 male US physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1312 men with a history of cancer at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011.
Intervention Daily multivitamin or placebo.
Main Outcome Measures Total cancer (excluding nonmelanoma skin cancer), with prostate, colorectal, and other site-specific cancers among the secondary end points.
Results During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2669 men with confirmed cancer, including 1373 cases of prostate cancer and 210 cases of colorectal cancer. Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total cancer (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P = .04). There was no significant effect of a daily multivitamin on prostate cancer (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P = .76), colorectal cancer (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P = .39), or other site-specific cancers. There was no significant difference in the risk of cancer mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P = .07). Daily multivitamin use was associated with a reduction in total cancer among 1312 men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P = .02), but this did not differ significantly from that among 13 329 men initially without cancer (HR, 0.94; 95% CI, 0.87-1.02; P = .15; P for interaction = .07)....."
Conclusion In this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer.
http://jama.jamanetwork.com/article.aspx?articleid=1380451
http://translate.google.de/translate?hl=de&sl=en&u=http://jama.jamanetwork.com/article.aspx%3Farticleid%3D1380451&prev=/search%3Fq%3D%28JAMA,%2Bonline%2BOct%2B17,2012%29%2Bvitamin%2Bcancer%26hl%3Dde%26biw%3D1024%26bih%3D606%26prmd%3Dimvns&sa=X&ei=UyeOUNWiPMfCtAbB4YDwAw&sqi=2&ved=0CDAQ7gEwAA
http://clinicaltrials.gov/show/NCT00270647